Skip to main content

Table 1 Characteristics of female sex workers (FSWs) and non-FSWs at their HAART initiation visit in Bobo-Dioulasso, Burkina Faso, 2004-2007

From: Long term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa

Characteristics

FSWs

(N = 47)

 

Non-FSWs

(N = 48)

 

P-value

 

n

(%)

n

(%)

 

Socio-demographic characteristics

     

   Age, median (IQR), years

31

(27, 35)

35

(31, 41)

0.01

   Education (n = 89)

    

0.86

Secondary

10

(22)

11

(26)

 

Primary

15

(32)

12

(28)

 

Illiterate

21

(46)

20

(46)

 

   Age at first sex, median (IQR), years (n = 89)

16

(15, 17)

16

(15, 18)

0.98

   Married (n = 89)

10

(22)

10

(23)

0.86

   Trip outside the city last 12 months (n = 89)

24

(52)

20

(47)

0.59

Behavioural characteristics

     

   Alcohol use in the last week

30

(64)

16

(33)

0.003

   Has a steady sexual partner at enrolment (n = 88)

37

(80)

21

(50)

0.003

   No. sexual intercourses in the last week, median (IQR), (n = 88)

2

(0-3)

0

(0-1)

< 0.001

   Always uses condoms with unknown casual sexual partners (n = 88)

35

(76)

31

(74)

0.81

   Always uses condoms with known sexual partners (n = 88)

25

(54)

30

(71)

0.10

   Always uses condoms with steady sexual partner(s) (n = 31)

3

(13)

3

(38)

0.16

Clinical and biological characteristics

     

   Body mass index, median (IQR), kg/m2

20.7

(18.4, 23.6)

19.0

(17.4, 21.8)

0.08

   WHO clinical stages (n = 88)*

    

0.94

Stage I

4

(8)

4

(9)

 

Stage II

10

(22)

9

(22)

 

Stage III

27

(59)

22

(52)

 

Stage IV

5

(11)

7

(17)

 

   CD4+ count, median (IQR), cells/μL (n = 95)

147

(79, 183)

144

(100, 197)

0.12

   Plasma HIV-1 RNA, mean (95% CI), log10 copies/ml (n = 92)

4.94

(4.70, 5.18)

5.15

(4.97, 5.33)

0.16

   HSV-2 seropositive

44

(94)

46

(96)

0.68

HAART regimen

    

0.11

   AZT/3TC/efavirenz

29

(62)

24

(50)

 

   d4T/3TC/nevirapine

10

(22)

12

(25)

 

   d4T/3TC/efavirenz

3

(6)

10

(21)

 

   AZT/3TC/nevirapine

3

(6)

1

(2)

 

   AZT/3TC/nelfinavir

2

(4)

0

(0)

 

   AZT/3TC/indinavir-ritonavir

0

(0)

1

(2)

 
  1. NOTE: Data are the no. (%) of women, unless otherwise indicated.
  2. AZT, zidovudine; d4T, stavudine; 3TC, lamivudine; HAART, highly active antiretroviral therapy; IQR, interquartile range.
  3. *5 missing values and in 2 patients, WHO clinical stage could not be determined at HAART initiation because of missing data such as weight loss or prior opportunistic diseases.